Italy's 14th Assisted Dying Case: Woman Uses Eye-Tracking Device After 2-Year Wait

A 55-year-old woman from Tuscany has become the 14th person in Italy to access medically assisted suicide, using a groundbreaking eye-tracking device engineered by Italy's National Research Council (CNR). After a two-year legal struggle, Libera self-administered lethal medication through the custom-designed technology—a first-of-its-kind solution that highlights how innovation can overcome legal barriers in Italy's fragmented assisted-dying system.

The Eye-Tracking Innovation

Libera's paralysis, caused by advanced multiple sclerosis, left her physically unable to self-administer medication in any conventional way. Under Italy's Constitutional Court ruling on assisted dying, patients must self-administer the lethal dose themselves—a legal distinction that separates assisted suicide from euthanasia. For severely paralyzed patients, this created an impossible barrier.

The solution came through legal action. A Tuscan civil court ordered the CNR to design an intravenous infusion system activated by eye-tracking technology. The device allowed Libera to trigger the lethal dose through deliberate eye movements, satisfying the constitutional requirement for self-administration while accommodating her physical limitations. Medical ethicists noted the technology also confirms ongoing consent in real time through repeated eye movements, addressing concerns about impulsive decisions.

The Two-Year Path to Access

Libera first qualified for assisted dying in July 2024 under criteria established by Italy's Constitutional Court in Ruling 242/2019, which decriminalized assisted suicide for patients with irreversible conditions causing unbearable suffering. Yet qualification did not mean swift access.

Italian law still does not codify the court's parameters, leaving each case to navigate a patchwork of regional health authorities, ethics committees, and tribunals. Libera's path required:

• Petition to her regional health service

• Evaluation by an ethics committee

• Court intervention when delays occurred

• Custom engineering solution to overcome physical barriers

Legal advocates estimate this process averages 18 to 24 months, even for clear-cut cases. For Libera, the two-year wait extended from her qualification in July 2024 through the device development and final authorization.

What This Means for Residents in Italy

For Italians facing terminal illness, Libera's case exposes both progress and persistent obstacles. The Constitutional Court ruling theoretically grants access nationwide, yet no standardized pathway exists. Geographic disparities compound the challenge: Tuscany has now seen two completed cases, but several southern regions report zero approved requests, in part due to local medical boards citing conscientious objection or procedural ambiguities.

The financial burden is another friction point. While medication is provided by Italy's National Health Service (SSN) once authorized, legal fees and private consultations often run into thousands of euros. Libera's custom device was state-funded under court order, but similar accommodations are not guaranteed without litigation.

For residents seeking to initiate the process, the first step is contacting your regional health service or consulting organizations like the Luca Coscioni Association, a Rome-based right-to-die advocacy group that has directly assisted 12 of the 14 completed cases and maintains a registry of applicants.

Why Parliament Hasn't Acted

Italy's assisted-dying framework remains entirely judge-made. Parliament has debated at least three bills since 2019 to establish clear procedures and waiting periods, but none has advanced past committee stage. Political deadlock—driven by opposition from Catholic and center-right lawmakers—has left the Constitutional Court's ruling as the sole legal anchor.

Prime Minister Giorgia Meloni's coalition has shown little appetite for advancing the issue, despite citizens' initiatives that gathered over 1.2 million signatures in 2021 for a referendum. The Constitutional Court ruled that ballot question inadmissible, citing procedural defects.

Libera's Final Message

In a statement released through the Luca Coscioni Association, Libera expressed hope that her ordeal would "shorten the wait" for others. She acknowledged her physician, Paolo Malacarne, for his willingness to participate despite professional risks—Italian doctors who assist can still face ethics board sanctions or criminal investigation if procedural steps are contested.

Her words carried a plea for legislative clarity: "This is a request for dignity that should one day be simply respected, not conquered." Advocacy groups have seized on her case as evidence that Italy's ad hoc system is unsustainable, particularly as demographic trends point to rising demand. An aging population and improving life-support technologies mean more Italians are living longer with chronic, debilitating conditions—exactly the cohort the Constitutional Court sought to protect.

For now, patients and families face a fragmented system where access depends on geography, resources, and judicial temperament. Libera's legacy may be measured not by immediate legislative reform, but by how her case—and the technological solution it spawned—shifts both public debate and future applications of assisted-dying rights.